Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | DT-7012 |
| Synonyms | |
| Therapy Description |
DT-7012 is a monoclonal antibody targeting CCR8, which potentially induces antibody-dependent cellular cytotoxicity (ADCC) and depletion of CCR8-positive regulatory T-cells (Cancer Res (2025) 85 (8_Supplement_1): 312). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| DT-7012 | DT 7012|DT7012 | CCR8 Antibody 13 | DT-7012 is a monoclonal antibody targeting CCR8, which potentially induces antibody-dependent cellular cytotoxicity (ADCC) and depletion of CCR8-positive regulatory T-cells (Cancer Res (2025) 85 (8_Supplement_1): 312). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06819735 | Phase Ib/II | DT-7012 DT-7012 + unspecified immune checkpoint inhibitor | Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors (DOMISOL) | Recruiting | AUS | 0 |